Low-Cost Antifibrinolytic Drug Shows Promise in Reducing Surgical Bleeding Worldwide

A landmark international trial spanning 22 countries has demonstrated that tranexamic acid, an inexpensive antifibrinolytic medication, significantly reduces bleeding complications in major noncardiac surgery. The POISE-3 trial enrolled 9,535 patients across 114 hospitals, making it one of the largest studies of its kind. Patients receiving tranexamic acid experienced composite bleeding outcomes in 9.1% of cases compared to 10.3% in the placebo group—an 11% relative reduction. The medication, costing less than $5 per dose, also reduced the need for red blood cell transfusions without increasing thromboembolic complications. These findings, published in The New England Journal of Medicine, suggest that tranexamic acid could become a standard intervention in surgical protocols globally, particularly benefiting healthcare systems with limited resources.